



# Talzenna in India

*The CDSCO named-patient coordination pathway — indicative 2026*

ONCOLOGY · HRR-MUTANT MCRPC & BRCA BREAST

## The clinical situation

Talzenna (talazoparib) is an FDA-approved oral PARP-1/2 inhibitor dosed 0.5 mg once daily in combination with enzalutamide for HRR-mutated metastatic castration-resistant prostate cancer, and 1 mg once daily monotherapy for germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. Manufactured by Pfizer. Requires documented HRR or BRCA testing.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating oncologist confirms HRR/BRCA status and documents a written clinical rationale and prior line history.
- 2 Treatment facility confirmed.** An Indian oncology centre (Delhi, Mumbai, Bengaluru, or Chennai tertiary facility) accepts the case and sets the treatment plan.
- 3 CDSCO named-patient application.** Clinical rationale, patient reference, product details, and chain-of-custody plan are filed with the Central Drugs Standard Control Organisation.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner, booked to your initiation date.
- 5 Arrival & administration.** The facility receives the product and initiates under your oncologist's care; ongoing cycles dispensed per the protocol.

### Indicative economics

**Reference US cash-pay range:** USD 16,000–18,000 per 30-day supply. CDSCO documentation, logistics, and concierge coordination are incremental. Full transparent quote at intake.

### Indicative first-dose timing

**7–14 days** from a complete CDSCO application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and CDSCO review. **Logistics.** Temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Talzenna × India first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/talzenna-india.html](https://reservemed.com/access-guides/talzenna-india.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team